ANCA-associated vasculitis (AAV) relapses occur more frequently during the summer and spring, particularly for people with granulomatosis with polyangiitis (GPA) or with anti-proteinase 3 (PR3) antibodies, a study in Japan reports. More frequent nasal infections caused by the bacterium Staphylococcus aureus during the summer in Japan may trigger inflammation…
Women and younger people with ANCA-associated vasculitis (AAV) tended to report worse health-related quality of life measures than do others in assessments, according to a review of published studies. More research is needed to assess disease-specific complaints about quality of life, the investigators said — and the team also…
End-stage kidney disease (ESKD) that required dialysis or a kidney transplant was associated with an elevated risk of death among people with ANCA-associated vasculitis (AAV), compared to patients who didn’t develop the complication, research indicates. A kidney transplant was associated with better prognosis compared to dialysis. On kidney biopsies,…
Most people with ANCA-associated vasculitis (AAV) experience acute or chronic kidney injury, according to a five-year national study in the U.S. More severe kidney damage is observed in people with the AAV disease type microscopic polyangiitis (MPA) than in those with granulomatosis with polyangiitis (GPA), and less severe symptoms are…
Long-term treatment with benralizumab — sold as Fasenra for a rare type of asthma — safely leads to clinical remission in up to two-thirds of people with eosinophilic granulomatosis with polyangiitis (EGPA), a real-world study shows. “Across a [two]-year period of treatment, we have observed extremely positive outcomes with benralizumab…
Tavneos (avacopan) improved kidney function and reduced the need for the glucocorticoid prednisone in four older patients who had signs of kidney failure due to ANCA-associated vasculitis (AAV), researchers in Canada report. While Tavneos may help patients enter into remission without the harmful side effects of glucocorticoids, “more…
A 64-year-old man with severe granulomatosis with polyangiitis (GPA) saw his condition improve with the use of a triple combination of standard cyclophosphamide and glucocorticoids along with the experimental therapy telitacicept, according to a case report from China. RemeGen’s telitacicept is approved in China under the brand name…
Treatment with Nucala (mepolizumab) for three or more years is safe, and was effective at easing symptoms and reducing the risk of relapse in people with eosinophilic granulomatosis with polyangiitis (EGPA), the most rare type of ANCA-associated vasculitis (AAV), a real-world study in Japan shows. Further, the need…
About half of people with granulomatosis with polyangiitis (GPA) have impairment of a valve in the heart, a study from Poland indicates. This heart valve dysfunction doesn’t cause notable problems for most patients, but a handful may have more severe complications that can require…
A worse physical health-related quality of life (HRQoL) at diagnosis was associated with a higher mortality risk among a group of ANCA-associated vasculitis (AAV) patients in Korea, according to a new report. This risk was particularly noted in people with the AAV types microscopic polyangiitis, or MPA, and granulomatosis…
Get regular updates to your inbox.